Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2019-09-29 Share Issue/Capital Cha…
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Appendix 3B 9 pages 278.2KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It contains detailed information about the issuance of new shares, including the number of securities issued, issue price, terms, and purpose (long-term incentive). It also includes sections on quotation of securities and agreements related to the listing on the ASX (Australian Securities Exchange). The document is regulatory in nature, focused on the announcement and application for quotation of new securities rather than a financial report or earnings release. This type of document corresponds to announcements about new share issues and capital changes. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length is substantial (over 14,000 characters), and it contains detailed information about the share issuance, not just a brief announcement or a link to a report, so it is not an RPA or RNS filing.
2019-09-29 English
Lapse of employee options 1 page 163.2KB
Transaction in Own Shares Classification · 95% confidence The document is a short announcement regarding the lapse of employee share options under the company's Employee Share Option Plan. It provides specific details about the number of options, expiry date, and exercise price. There is no financial report, earnings data, or detailed analysis. The content relates to a transaction or change in the company's own shares (employee options lapsing). Therefore, the most appropriate classification is 'Transaction in Own Shares' (POS). The document length is short and focused on share option changes, not a full report or announcement of a report publication.
2019-09-15 English
PBS listing for KAPANOL in chronic breathlessness 3 pages 121.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 27 August 2019 regarding the Pharmaceutical Benefits Scheme (PBS) listing of KAPANOL for chronic breathlessness. It provides detailed information about the product, its new indication, clinical study references, and usage guidelines. The document is a public announcement of a regulatory approval and product listing, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. The length is 7671 characters, which is moderate, but the content is clearly an announcement of a new product listing on PBS rather than a report or presentation. Therefore, the document fits best into the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2019-08-26 English
Appendix 4E and Full Year Statutory Accounts 77 pages 1.7MB
Annual Report Classification · 100% confidence The document is dated 23 August 2019 and is titled as a Preliminary Final Report for the year ended 30 June 2019. It includes an Appendix 4E and Annual Financial Statements, which are typical components of a full year financial report. The content includes detailed financial statements such as the Consolidated Statement of Profit or Loss, Statement of Financial Position, Cash Flows, and Notes to the Financial Statements. It also contains a Directors' Report, Remuneration Report, Auditor's Independence Declaration, and an Independent Auditor's Report. The document covers the full fiscal year and provides comprehensive financial performance data, management discussion, and audit information. This matches the characteristics of an Annual Report (10-K equivalent) rather than a mere announcement or a partial report. The length of the document (15,000 characters) and the detailed financial data confirm it is the full report, not just an announcement of the report. Therefore, the correct classification is Annual Report (10-K). FY 2019
2019-08-22 English
2019 Full Year Results Media Release 5 pages 169.1KB
Earnings Release Classification · 95% confidence The document is an ASX announcement dated 23 August 2019 reporting the full fiscal year 2019 (FY19) financial results of Mayne Pharma. It includes detailed financial metrics such as revenues, gross profit, EBITDA, net loss, cash flow, segment performance, pipeline updates, debt and cash flow status, and outlook for FY20. The content is comprehensive and covers the company's full-year financial performance and operational highlights, which aligns with the characteristics of an Annual Report or full-year financial results announcement. However, it is not a full Annual Report (10-K) filing but rather a detailed Earnings Release (ER) as it primarily focuses on key financial results and business highlights for the fiscal year without the extensive disclosures typical of a 10-K. The document length (13,838 characters) and detailed financial data support classification as an Earnings Release rather than a brief summary or announcement of report publication. Therefore, the most appropriate classification is Earnings Release (ER). FY 2019
2019-08-22 English
2019 Full Year Results Investor Presentation 29 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is titled 'FY19 Results Presentation 23 August 2019' and contains detailed financial results for the fiscal year 2019, including revenue, EBITDA, net loss, segment performance, and operational highlights. It includes forward-looking statements, non-IFRS financial information, and strategic priorities. The document is a presentation format with charts and tables summarizing the company's financial performance and business strategy. It is not a full annual report (10-K) but a detailed presentation aimed at investors and analysts summarizing the fiscal year results. It is not a brief factsheet or earnings release since it contains comprehensive financial data and strategic commentary. Therefore, the document fits the definition of an Investor Presentation (IP). The document length (15,000 characters) and content support this classification with high confidence.
2019-08-22 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.